Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Про- и синбиотики в лечении заболеваний кишечника: на какие эффекты мы можем рассчитывать?
Про- и синбиотики в лечении заболеваний кишечника: на какие эффекты мы можем рассчитывать?
Гаус О.В., Ливзан М.А. Про- и синбиотики в лечении заболеваний кишечника: на какие эффекты мы можем рассчитывать? Consilium Medicum. 2020; 22 (12): 37–43. DOI: 10.26442/20751753.2020.12.200309
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Связь между кишечной микробиотой и состоянием здоровья человека является общепризнанной. Появление молекулярных и генетических методов диагностики позволило сделать поистине революционные открытия в области понимания роли микробиома пищеварительного тракта. Во многих исследованиях доказана ассоциация измененного под воздействием факторов окружающей среды состава микробиоты с развитием целого ряда заболеваний пищеварительного тракта, таких как воспалительные заболевания кишечника, функциональные гастроинтестинальные расстройства, некоторые виды рака. Одновременно с этим пищевая и фармацевтическая промышленность представила огромный выбор продуктов питания, биологически активных добавок и лекарственных средств, содержащих пребиотические и пробиотические компоненты. Несмотря на растущее число исследований по эффективности средств, влияющих на микробиоту, их применение в реальной клинической практике должно осуществляться строго в соответствии с показаниями, в рекомендованных дозах.
Ключевые слова: микробиота, пробиотики, пребиотики, синбиотики, метабиотики, функциональные гастроинтестинальные расстройства, воспалительные заболевания кишечника.
Key words: microbiota, probiotics, prebiotics, synbiotics, metabiotics, functional gastrointestinal disorders, inflammatory bowel diseases.
Ключевые слова: микробиота, пробиотики, пребиотики, синбиотики, метабиотики, функциональные гастроинтестинальные расстройства, воспалительные заболевания кишечника.
________________________________________________
Key words: microbiota, probiotics, prebiotics, synbiotics, metabiotics, functional gastrointestinal disorders, inflammatory bowel diseases.
Полный текст
Список литературы
1. Jandhyala SM, Talukdar R, Subramanyam C et al. Role of the normal gut microbiota. World J Gastroenterol 2015; 21 (29): 8787–803.
2. Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734–6.
3. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319–30.
4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805–20.
5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812–26.
6. Alakomi HL, Skyttä E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001–5.
7. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101–12.
8. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.
9. Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.
10. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728–33.
11. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325–7.
12. Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831–5.
13. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971–5.
14. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1–2): 127–35.
15. Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53–60.
16. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559–63.
17. McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031–18.
18. Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906–18.
19. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56–66.
20. Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96–9.
21. Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.
22. Гаус О.В., Ливзан М.А. Синдром раздраженного кишечника: что мы знаем о симптомах сегодня? Consilium Medicum. 2019; 21 (8): 42–8.
[Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42–8 (in Russian).]
23. Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальной боли в молодежной среде: распространенность и факторы риска. Эксперим. и клин. гастроэнтерология. 2019; 170 (10): 12–7.
[Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Sindrom abdominal'noĭ boli v molodezhnoĭ srede: rasprostranennost' i faktory riska. Eksperim. i klin. gastroenterologiia. 2019; 170 (10): 12–7 (in Russian).]
24. Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593–627.
25. Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сиб. журн. гастроэнтерологии и гепатологии. 2000; 10: 32.
[Kostenko M.B., Livzan M.A. Mekhanizmy razvitiia sindroma razdrazhennogo kishechnika. Sib. zhurn. gastroenterologii i gepatologii. 2000; 10: 32 (in Russian).]
26. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497–505.
27. Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.
28. Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.
29. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori – простые следы или серьезные последствия? Лечащий врач. 2011; 7: 7.
[Livzan M.A., Mozgovoi S.I., Kononov A.V. Gastrit posle eradikatsii Helicobacter pylori – prostye sledy ili ser'eznye posledstviia? Lechashchii vrach. 2011; 7: 7 (in Russian).]
30. Tilg G, Schmiderer A, Djanani A. Gut microbiom – immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.
31. Глобальные практические рекомендации Всемирной Гастроэнтерологической Организации. Пробиотики и пребиотики. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20...
[Global Practice Guidelines of the World Gastroenterological Organization. Probiotics and prebiotics. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20... (in Russian).]
32. Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.
33. Kankaanpää P, Sütas Y, Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269–77.
34. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58–64.
35. Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353–9.
36. Ливзан М.А., Костенко М.Б. Место пробиотической терапии в лечении и профилактике антибиотик-ассоциированной диареи. Лечащий врач. 2010; 10: 83.
[Livzan M.A., Kostenko M.B. Mesto probioticheskoi terapii v lechenii i profilaktike antibiotik-assotsiirovannoi diarei. Lechashchii vrach. 2010; 10: 83 (in Russian).]
37. Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458–63.
38. Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.
39. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125–34.
40. Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.
41. Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017; 3 (13): 49–55.
[Akhmedov V.A., Orlov I.N., Gaus O.V. Sovremennye metody reabilitatsii patsientov s sindromom razdrazhennogo kishechnika. Terapiia. 2017; 3 (13): 49–55 (in Russian).]
42. Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.
43. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.
44. Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415–21.
45. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315–20.
46. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.
47. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.
48. Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675–93.
2. Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734–6.
3. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319–30.
4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805–20.
5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812–26.
6. Alakomi HL, Skyttä E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001–5.
7. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101–12.
8. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.
9. Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.
10. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728–33.
11. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325–7.
12. Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831–5.
13. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971–5.
14. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1–2): 127–35.
15. Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53–60.
16. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559–63.
17. McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031–18.
18. Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906–18.
19. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56–66.
20. Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96–9.
21. Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.
22. Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42–8 (in Russian).
23. Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Sindrom abdominal'noĭ boli v molodezhnoĭ srede: rasprostranennost' i faktory riska. Eksperim. i klin. gastroenterologiia. 2019; 170 (10): 12–7 (in Russian).
24. Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593–627.
25. Kostenko M.B., Livzan M.A. Mekhanizmy razvitiia sindroma razdrazhennogo kishechnika. Sib. zhurn. gastroenterologii i gepatologii. 2000; 10: 32 (in Russian).
26. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497–505.
27. Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.
28. Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.
29. Livzan M.A., Mozgovoi S.I., Kononov A.V. Gastrit posle eradikatsii Helicobacter pylori – prostye sledy ili ser'eznye posledstviia? Lechashchii vrach. 2011; 7: 7 (in Russian).
30. Tilg G, Schmiderer A, Djanani A. Gut microbiom – immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.
31. Global Practice Guidelines of the World Gastroenterological Organization. Probiotics and prebiotics. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20... (in Russian).
32. Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.
33. Kankaanpää P, Sütas Y, Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269–77.
34. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58–64.
35. Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353–9.
36. Livzan M.A., Kostenko M.B. Mesto probioticheskoi terapii v lechenii i profilaktike antibiotik-assotsiirovannoi diarei. Lechashchii vrach. 2010; 10: 83 (in Russian).
37. Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458–63.
38. Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.
39. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125–34.
40. Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.
41. Akhmedov V.A., Orlov I.N., Gaus O.V. Sovremennye metody reabilitatsii patsientov s sindromom razdrazhennogo kishechnika. Terapiia. 2017; 3 (13): 49–55 (in Russian).
42. Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.
43. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.
44. Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415–21.
45. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315–20.
46. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.
47. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.
48. Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675–93.
2. Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734–6.
3. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319–30.
4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805–20.
5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812–26.
6. Alakomi HL, Skyttä E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001–5.
7. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101–12.
8. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.
9. Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.
10. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728–33.
11. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325–7.
12. Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831–5.
13. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971–5.
14. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1–2): 127–35.
15. Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53–60.
16. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559–63.
17. McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031–18.
18. Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906–18.
19. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56–66.
20. Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96–9.
21. Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.
22. Гаус О.В., Ливзан М.А. Синдром раздраженного кишечника: что мы знаем о симптомах сегодня? Consilium Medicum. 2019; 21 (8): 42–8.
[Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42–8 (in Russian).]
23. Ливзан М.А., Гаус О.В., Турчанинов Д.В., Попелло Д.В. Синдром абдоминальной боли в молодежной среде: распространенность и факторы риска. Эксперим. и клин. гастроэнтерология. 2019; 170 (10): 12–7.
[Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Sindrom abdominal'noĭ boli v molodezhnoĭ srede: rasprostranennost' i faktory riska. Eksperim. i klin. gastroenterologiia. 2019; 170 (10): 12–7 (in Russian).]
24. Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593–627.
25. Костенко М.Б., Ливзан М.А. Механизмы развития синдрома раздраженного кишечника. Сиб. журн. гастроэнтерологии и гепатологии. 2000; 10: 32.
[Kostenko M.B., Livzan M.A. Mekhanizmy razvitiia sindroma razdrazhennogo kishechnika. Sib. zhurn. gastroenterologii i gepatologii. 2000; 10: 32 (in Russian).]
26. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497–505.
27. Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.
28. Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.
29. Ливзан М.А., Мозговой С.И., Кононов А.В. Гастрит после эрадикации Helicobacter pylori – простые следы или серьезные последствия? Лечащий врач. 2011; 7: 7.
[Livzan M.A., Mozgovoi S.I., Kononov A.V. Gastrit posle eradikatsii Helicobacter pylori – prostye sledy ili ser'eznye posledstviia? Lechashchii vrach. 2011; 7: 7 (in Russian).]
30. Tilg G, Schmiderer A, Djanani A. Gut microbiom – immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.
31. Глобальные практические рекомендации Всемирной Гастроэнтерологической Организации. Пробиотики и пребиотики. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20...
[Global Practice Guidelines of the World Gastroenterological Organization. Probiotics and prebiotics. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20... (in Russian).]
32. Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.
33. Kankaanpää P, Sütas Y, Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269–77.
34. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58–64.
35. Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353–9.
36. Ливзан М.А., Костенко М.Б. Место пробиотической терапии в лечении и профилактике антибиотик-ассоциированной диареи. Лечащий врач. 2010; 10: 83.
[Livzan M.A., Kostenko M.B. Mesto probioticheskoi terapii v lechenii i profilaktike antibiotik-assotsiirovannoi diarei. Lechashchii vrach. 2010; 10: 83 (in Russian).]
37. Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458–63.
38. Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.
39. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125–34.
40. Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.
41. Ахмедов В.А., Орлов И.Н., Гаус О.В. Современные методы реабилитации пациентов с синдромом раздраженного кишечника. Терапия. 2017; 3 (13): 49–55.
[Akhmedov V.A., Orlov I.N., Gaus O.V. Sovremennye metody reabilitatsii patsientov s sindromom razdrazhennogo kishechnika. Terapiia. 2017; 3 (13): 49–55 (in Russian).]
42. Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.
43. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.
44. Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415–21.
45. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315–20.
46. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.
47. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.
48. Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675–93.
________________________________________________
2. Cresci GA. The gut microbiome: what we do and don't know. Nutr Clin Pract 2015; 30 (6): 734–6.
3. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr Gastroenterol Rep 2010; 12 (5): 319–30.
4. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010; 140 (6): 805–20.
5. He B, Xu W, Santini PA et al. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. Immunity 2007; 26 (6): 812–26.
6. Alakomi HL, Skyttä E, Saarela M et al. Lactic acid permeabilizes gram-negative bacteria by disrupting the outer membrane. Appl Environ Microbiol 2000; 66 (5): 2001–5.
7. Velagapudi VR, Hezaveh R, Reigstad CS et al. The gut microbiota modulates host energy and lipid metabolism in mice. J Lipid Res 2010; 51 (5): 1101–12.
8. Azad MAK, Sarker M, Wan D. Immunomodulatory effects of probiotics on cytokine profiles. Biomed Res Int 2018; 8063647: 2018.
9. Defois C, Ratel J, Garrait G et al. Food chemicals disrupt human gut microbiota activity and impact intestinal homeostasis as revealed by in vitro systems. Sci Rep 2018; 8 (1): 11006.
10. Clayton TA, Baker D, Lindon JC et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A 2009; 106 (34): 14728–33.
11. Saha JR, Butler VP Jr, Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983; 220 (4594): 325–7.
12. Wallace BD, Wang H, Lane KT et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330 (6005): 831–5.
13. Dominguez-Bello MG, Costello EK, Contreras M et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A 2010; 107 (26): 11971–5.
14. Sherman MP, Zaghouani H, Niklas V. Gut microbiota, the immune system, and diet influence the neonatal gut-brain axis. Pediatr Res 2015; 77 (1–2): 127–35.
15. Zimmer J, Lange B, Frick JS et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr 2012; 66: 53–60.
16. David LA, Maurice CF, Carmody RN et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014; 505 (7484): 559–63.
17. McDonald D, Hyde E, Debelius JW et al. American gut: an open platform for citizen science microbiome research. mSystems 2018; 3 (3): e00031–18.
18. Prideaux L, Kang S, Wagner J et al. Impact of ethnicity, geography, and disease on the microbiota in health and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2906–18.
19. Jernberg C, Löfmark S, Edlund C, Jansson JK. Long-term ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J 2007; 1 (1): 56–66.
20. Ng KM, Ferreyra JA, Higginbottom SK et al. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature 2013; 502 (7469): 96–9.
21. Chong PP, Chin VK, Looi CY et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Front Microbiol 2019; 10: 1136.
22. Gaus O.V., Livzan M.A. Irritable bowel syndrome: what do we know about symptoms today? Consilium Medicum. 2019; 21 (8): 42–8 (in Russian).
23. Livzan M.A., Gaus O.V., Turchaninov D.V., Popello D.V. Sindrom abdominal'noĭ boli v molodezhnoĭ srede: rasprostranennost' i faktory riska. Eksperim. i klin. gastroenterologiia. 2019; 170 (10): 12–7 (in Russian).
24. Sinagra E, Morreale GE, Mohammadian G et al. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immune-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol 2017; 23 (36): 6593–627.
25. Kostenko M.B., Livzan M.A. Mekhanizmy razvitiia sindroma razdrazhennogo kishechnika. Sib. zhurn. gastroenterologii i gepatologii. 2000; 10: 32 (in Russian).
26. Collins SM. A role for the gut microbiota in IBS. Nat Rev Gastroenterol Hepatol 2014; 11: 497–505.
27. Khan I, Ullah N, Zha L et al. Alteration of the gut microbiota in inflammatory bowel disease (IBD): cause of consequence? IBD treatment targeting the gut microbiome. Pathogens 2019; 8 (3): 126.
28. Mentella MC, Scaldaferri F, Pizzoferrato M et al. Nutrition, IBD and gut microbiota: a review. Nutrients 2020; 12 (4): 944.
29. Livzan M.A., Mozgovoi S.I., Kononov A.V. Gastrit posle eradikatsii Helicobacter pylori – prostye sledy ili ser'eznye posledstviia? Lechashchii vrach. 2011; 7: 7 (in Russian).
30. Tilg G, Schmiderer A, Djanani A. Gut microbiom – immune crosstalk affects progression of cancer. Transl Gastroenterol Hepatol 2018; 3: 34.
31. Global Practice Guidelines of the World Gastroenterological Organization. Probiotics and prebiotics. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-russian-20... (in Russian).
32. Harper A, Naghibi M, Garcha D. The role of bacteria, probiotics and diet in irritable bowel syndrome. Foods 2018; 7 (2): 13.
33. Kankaanpää P, Sütas Y, Salminen S, Isolauri E. Homogenates derived from probiotic bacteria provide down-regulatory signals for peripheral blood mononuclear cells. Food Chemistry 2003; 83 (2): 269–77.
34. Bodera P, Chcialowski A. Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov 2009; 3 (1): 58–64.
35. Maroof H, Mohammad Hassan Z, Mohabati Mobarez A, Azimi Mohamadabadi M. Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model. J Clin Immunol 2012; 32: 1353–9.
36. Livzan M.A., Kostenko M.B. Mesto probioticheskoi terapii v lechenii i profilaktike antibiotik-assotsiirovannoi diarei. Lechashchii vrach. 2010; 10: 83 (in Russian).
37. Ouwehand AC, DongLian C, Weijian X et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: A randomized dose response study. Vaccine 2014; 2 (4): 458–63.
38. Goldenberg JZ, Yap C, Lytvyn L et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12: CD006095.
39. Parker EA, Roy T, D’Adamo CR, Wieland LS. Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration. Nutrition 2018; 45 (2018): 125–34.
40. Li B, Liang L, Deng H et al. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis. Front Pharmacol 2020; 11: 332.
41. Akhmedov V.A., Orlov I.N., Gaus O.V. Sovremennye metody reabilitatsii patsientov s sindromom razdrazhennogo kishechnika. Terapiia. 2017; 3 (13): 49–55 (in Russian).
42. Connel M, Shin A, James-Stevenson T et al. Systematic review and meta-analysis: efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018; 30 (12): e13427.
43. Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulatio in the management of diarrhea-predominant irritable bowel syndrome. BMC Gastroenterol 2018; 18 (1): 71.
44. Sun J, Wang F, Hu X et al. Clostridium butyricum attenuates chronic unpredictable mild stress-induced depressive-like behavior in mice via the gut-brain axis. J Agric Food Chem 2018; 66 (31): 8415–21.
45. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. Nutrition 2016; 32 (3): 315–20.
46. Rao AV, Bested AC, Beaulne TM et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009; 1 (1): 6.
47. Wallace CJK, Milev R. The effects of probiotics on depressive symptoms in humans: a systematic review. Ann Gen Psychiatry 2017; 16 (1): 14.
48. Romijn AR, Rucklidge JJ. Systematic review of evidence to support the theory of psychobiotics. Nutr Rev 2015; 73 (10): 675–93.
Авторы
О.В. Гаус*, М.А. Ливзан
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*gaus_olga@bk.ru
Omsk State Medical University, Omsk, Russia
*gaus_olga@bk.ru
ФГБОУ ВО «Омский государственный медицинский университет» Минздрава России, Омск, Россия
*gaus_olga@bk.ru
________________________________________________
Omsk State Medical University, Omsk, Russia
*gaus_olga@bk.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.